In a clinical study, systemic exposure to eltrombopag was decreased by 70% when it was administered with a polyvalent cation-containing antacid. Naproxen; Esomeprazole: (Moderate) Eltrombopag is a UDP-glucuronyltransferase inhibitor. In the phase III PETIT2 trial, 92 patients were randomized to eltrombopag (n = 63) or placebo (n = 29). Comment: Coadministration of ozanimod (a BCRP substrate) with BCRP inhibitors increases the exposure of the minor (RP101988, RP101075) and major active metabolites (CC112273, CC1084037) of ozanimod, which may increase the risk of ozanimod adverse reactions. Hypersensitivity to eltrombopag or any component of the formulation; severe hepatic impairment (Child-Pugh class C). Patients of Asian ancestry (e.g. Use Caution/Monitor. Aspirin, ASA; Omeprazole: (Moderate) Eltrombopag is metabolized by CYP1A2. Monitor Closely (1)eltrombopag increases levels of opium tincture by decreasing metabolism. Anon. Indications. Annotation of HCSC Label for Eltrombopag and F5, SERPINC1. eltrombopag will increase the level or effect of deferiprone by decreasing metabolism. Todays label expansion for Promacta provides a new disease management option for families affected by chronic ITP and highlights our commitment to providing treatments for even the youngest children with rare diseases.. Monitor patients for adverse reactions if these drugs are coadministered. The significance or effect of this interaction is not known; however, elevated concentrations of the NSAID are possible. amiodarone will increase the level or effect of eltrombopag by affecting hepatic enzyme CYP2C9/10 metabolism. Monitor Closely (1)eltrombopag increases levels of berotralstat by Other (see comment). Separate by at least 4 hours. Separate by at least 4 hours. Consider alternative treatment for worsening thrombocytopenia. Monitor ALT, AST, and bilirubin at baseline, every other day while hospitalized for horse antithymocyte (h-ATG) therapy, and every 2 weeks afterward.12 years and older: Reduce the initial dose to 75 mg PO once daily.6 to 11 years: Reduce the initial dose to 37.5 mg PO once daily.2 to 5 years: Reduce the initial dose to 1.25 mg/kg PO once daily.Discontinue eltrombopag if ALT/AST concentrations increase more than 6 times the ULN; may reinitiate treatment at the same dose once the AST/ALT is less than 5 times the ULN. In the double-blind portion of the trial, 67 patients were randomized to eltrombopag (n = 45) or placebo (n = 22). Monitor patients for adverse reactions if these drugs are coadministered. Acetaminophen; Caffeine: (Moderate) Eltrombopag is a UDP-glucuronyltransferase inhibitor. In this group, 80% of patients achieved platelet counts of 50109 per liter or more at least once. Use Caution/Monitor. The effects of this transporter on the concentrations of maraviroc are unknown, although an increase in concentrations and thus, toxicity, are possible. In vitro studies have found that CYP1A2 and CYP2C8 are responsible for the oxidative metabolism of eltrombopag, and UGT1A1 and UGT1A3 are responsible for glucuronidation. Eltrombopag is an inhibitor of the transporter OATP1B1. Properly discard this product when it is expired or no longer needed. Concurrent use may increase berotralstat exposure and the risk of adverse effects. Separate by at least 4 hours. Phenobarbital; Hyoscyamine; Atropine; Scopolamine: (Moderate) Eltrombopag is metabolized by CYP1A2. butalbital will decrease the level or effect of eltrombopag by affecting hepatic enzyme CYP1A2 metabolism. All rights reserved. Use Caution/Monitor.amobarbital will decrease the level or effect of eltrombopag by affecting hepatic enzyme CYP2C9/10 metabolism. Maximum dose: 150 mg/day. If platelets are more than 400,000/mm3 after 2 weeks of the lowest dose, discontinue eltrombopag. Monitor patients for adverse reactions if these drugs are coadministered. The significance or effect of this interaction is not known; however, elevated concentrations of acetaminophen are possible. Isoniazid, INH; Pyrazinamide, PZA; Rifampin: (Major) Eltrombopag is metabolized by CYP1A2 and CYP2C8. Contraindicated. Acetaminophen; Dextromethorphan; Doxylamine: (Moderate) Eltrombopag is a UDP-glucuronyltransferase inhibitor. Use Caution/Monitor. Contraindicated. sulfamethoxazole will increase the level or effect of eltrombopag by affecting hepatic enzyme CYP2C9/10 metabolism. Celecoxib; Tramadol: (Moderate) Eltrombopag is a UDP-glucuronyltransferase inhibitor. Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection. Treatment of Primary Immune Thrombocytopenia (ITP) Treatment. For platelets 200,000 to 400,000/mm3, decrease the dose by 12.5 mg/day every 2 weeks to the lowest dose that maintains a platelet count of 50,000/mm3 or more. Use Caution/Monitor. (Major) Eltrombopag chelates polyvalent cations (e.g., calcium, aluminum, and magnesium) in food. Monitor Closely (1)tobacco use will decrease the level or effect of eltrombopag by affecting hepatic enzyme CYP1A2 metabolism. fluvoxamine will increase the level or effect of eltrombopag by affecting hepatic enzyme CYP1A2 metabolism. Serious - Use Alternative (1)calcium acetate decreases levels of eltrombopag by inhibition of GI absorption. Monitor Closely (1)eltrombopag increases levels of acetaminophen by decreasing metabolism. Monitor patients for adverse reactions if these drugs are coadministered. Pharmacogenomics Knowledgebase (PharmGKB). Traductions en contexte de "Les contre-indications pour les mdicaments" en franais-polonais avec Reverso Context : Les contre-indications pour les mdicaments sont les mmes. ferric maltol decreases levels of eltrombopag by inhibition of GI absorption. This agent appears to possess many of the desirable properties for a treatment for chemotherapy induced thrombocytopenia, including oral administration. Applies only to oral form of both agents. eltrombopag will increase the level or effect of riociguat by P-glycoprotein (MDR1) efflux transporter. The significance or effect of this interaction is not known; however, elevated concentrations of the NSAID are possible. Common side effects of eltrombopag may include: nausea, diarrhea; fever; cough; headache, tiredness; anemia; or. Acetaminophen is a substrate of UDP-glucuronyltransferases. The significance of administering inducers of CYP1A2, such as ritonavir, on the systemic exposure of eltrombopag has not been established. Not intended for use to normalise platelet count. Use Caution/Monitor. The significance or effect of this interaction is not known; however, elevated concentrations of acetaminophen are possible. Use Caution/Monitor. If new cytogenetic abnormalities are observed, consider discontinuation of PROMACTA. Drugs that are substrates for this transporter, such as repaglinide, may exhibit an increase in systemic exposure if coadministered with eltrombopag; monitor patients for adverse reactions if these drugs are coadministered. Advise patients against driving or operating machinery until the combine effects of these drugs on the individual patient is known. UGT inhibition; significance of interaction unclear. Eltrombopag is an inhibitor of the transporter OATP1B1. Monitor patients for signs of eltrombopag toxicity if these drugs are coadministered. Or click OK to continue. If the ALT/AST returns to more than 6 times the ULN on the reduced dose, reduce the dose by 25 mg/day until the ALT/AST is less than 5 times the ULN. Adjust the dose based on platelet count. Applies only to oral form of both agents. If not used right away, the mixed medication may be stored at room temperature for up to 30 minutes. https://www.medicinescomplete.com. India is the world's capital for quality medicines, be it pharmaceutical formulations, herbal medicines or nutraceuticals. Avoid or Use Alternate Drug. (Moderate) Caution is advised with the coadministration of pibrentasvir and eltrombopag as coadministration may increase serum concentrations of pibrentasvir and increase the risk of adverse effects. Use Caution/Monitor. REVOLADE (eltrombopag) is the thrombopoietin receptor agonist (TPO-RA) proven in the most disease states: adult and paediatric chronic immune thrombocytopenia (ITP), adult and paediatric severe aplastic anaemia (SAA), and chronic hepatitis C virusassociated thrombocytopenia (HCVaT). Eltrombopag is an inhibitor of the transporter OATP1B1. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. Separate by at least 4 hours. Use Caution/Monitor. Niacin; Simvastatin: (Moderate) Use caution and monitor for adverse reactions if eltrombopag and simvastatin are coadministered. Sacubitril; Valsartan: (Moderate) Use caution and monitor blood pressure closely if eltrombopag and valsartan are coadministered. Drugs that are substrates for this transporter, such as glyburide, may exhibit an increase in systemic exposure if coadministered with eltrombopag. The significance or effect of this interaction is not known; however, elevated concentrations of the NSAID are possible. The significance of administering inducers of CYP1A2, such as barbiturates, on the systemic exposure of eltrombopag has not been established. eltrombopag increases levels of acetaminophen rectal by decreasing metabolism. Monitor Closely (1)eltrombopag increases levels of meperidine by decreasing metabolism. The significance or effect of this interaction is not known; however, elevated concentrations of acetaminophen are possible. Use Caution/Monitor. iron dextran complex decreases levels of eltrombopag by inhibition of GI absorption. Thiopental: (Moderate) Eltrombopag is metabolized by CYP1A2. UGT inhibition; significance of interaction unclear. The risk of bleeding and recurrent thrombocytopenia is increased in patients receiving these drugs when eltrombopag is discontinued. To help you remember, take it at the same time each day. Monitor patients for signs of eltrombopag toxicity if these drugs are coadministered. [40392], 2.5 mg/kg/dose PO once daily initially; for patients of East/Southeast-Asian ancestry, 1.25 mg/kg/dose PO once daily. Use Caution/Monitor.pentobarbital will decrease the level or effect of eltrombopag by affecting hepatic enzyme CYP2C9/10 metabolism. Elimination occurs primarily by the feces (59%) and the urine (31%); unchanged drug accounts for approximately 20% of the dose in the feces, and unchanged drug is not detected in the urine. Use Caution/Monitor. Serious - Use Alternative (1)eltrombopag increases toxicity of pravastatin by Other (see comment). abnormal bone marrow or liver function tests. 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. https://www.pharmgkb.org/. Applies only to oral form of both agents. Hydrocodone; Ibuprofen: (Moderate) Eltrombopag is a UDP-glucuronyltransferase inhibitor. Once the platelet count is less than 200,000/mm3, reinitiate at a dose reduced by 12.5 mg/day. In the trials, eltrombopag was compared with placebo for 159 patients aged 1 to 17 with chronic ITP. Use Caution/Monitor. Contraindicated. For platelets 200,000 to 400,000/mm3, decrease the dose by 25 mg/day PO; wait 2 weeks to assess the effects of any dosage adjustments. eltrombopag increases levels of sulfasalazine by decreasing metabolism. Mefenamic Acid: (Moderate) Eltrombopag is a UDP-glucuronyltransferase inhibitor. Abopa is a thrombopoietin receptor agonist, which treats the following indications: Treatment of chronic immune response This drug is available at a higher level co-pay. Use Caution/Monitor. Administer eltrombopag 2 hours before or 4 hours after any oral products containing zinc salts. Use Caution/Monitor. If unable to avoid or use alternant drugs, closely monitor for increased adverse reactions. Separate by at least 4 hours. Use Caution/Monitor. Selexipag is a ABCG2 (BCRP) substrate. Indicated in patients with insufficient response to corticosteroids, immunoglobulins, or splenectomy, Use only in patients with ITP whose clinical condition increases bleeding risk, Maintenance: Adjust dose to achieve and maintain platelet count (Plt) >50 x 10^9/L to reduce risk of bleeding; not to exceed 75 mg/day, Indicated to allow initiation and maintenance of interferon-based therapy, Adjust dose in 25 mg increments q2weeks PRN to achieve target platelet count required to initiate/maintain antiviral therapy with pegylated interferon and ribavirin; not to exceed 100 mg/day, During antiviral therapy, adjust dose to avoid dose reductions of peginterferon, During therapy, assess complete blood cell counts (CBCs) weekly until a stable Plt is achieved; obtain CBCs with differentials, monthly thereafter, Measure ALT, AST, and bilirubin prior to initiation of therapy, every other day while hospitalized for horse antithymocyte globulin (h-ATG) therapy, and then every 2 weeks during treatment, Indicated for treatment of thrombocytopenia in adults and pediatric patients 1 yr with chronic immune (idiopathic) thrombocytopenia (ITP) with insufficient response to corticosteroids, immunoglobulins, or splenectomy; use only in patients with ITP whose clinical condition increases bleeding risk, <1 year: Safety and efficacy not established, When switching between oral suspension and tablet, assess platelets weekly for 2 weeks, and then follow standard monthly monitoring. Contraindicated. Avoid or Use Alternate Drug. Use Caution/Monitor. eltrombopag increases levels of ketorolac intranasal by decreasing metabolism. Use Caution/Monitor. The risk of bleeding and recurrent thrombocytopenia is increased in patients receiving these drugs when eltrombopag is discontinued. The reconstituted suspension will be dark brown in color.Place the tip of the oral dosing syringe into the patient's mouth against the inside of the cheek and slowly eject the dose.Carefully clean up any spill of the powder or suspension with a damp paper towel or disposable cloth. NSAIDs are a substrate of UDP-glucuronyltransferases. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. Topotecan is a substrate of the efflux transporter BCRP. Acetaminophen; Dextromethorphan; Phenylephrine: (Moderate) Eltrombopag is a UDP-glucuronyltransferase inhibitor. Serious - Use Alternative (1)aluminum hydroxide decreases levels of eltrombopag by inhibition of GI absorption. The significance or effect of this interaction is not known; however, elevated concentrations of the NSAID are possible. eltrombopag increases levels of hydromorphone by decreasing metabolism. Applies only to oral form of both agents. The significance or effect of this interaction is not known; however, elevated concentrations of the NSAID are possible. miconazole vaginal will increase the level or effect of eltrombopag by affecting hepatic enzyme CYP2C9/10 metabolism. The risk of bleeding and recurrent thrombocytopenia is increased in patients receiving these drugs when eltrombopag is discontinued. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Monitor Closely (1)magnesium supplement will decrease the level or effect of eltrombopag by Other (see comment). The significance of administering inducers of CYP1A2, such as barbiturates, on the systemic exposure of eltrombopag has not been established. Applies only to oral form of both agents. Use Caution/Monitor. UGT inhibition; significance of interaction unclear. Monitor patients for adverse reactions if these drugs are coadministered. Monitor patients for a decrease in the efficacy of eltrombopag if these drugs are coadministered. Use Caution/Monitor. eltrombopag increases levels of tolmetin by decreasing metabolism. The significance or effect of this interaction is not known; however, elevated concentrations of the NSAID are possible. Monitor Closely (1)eltrombopag increases levels of flurbiprofen by decreasing metabolism. Therapeutic uses, prescribing information and product availability may vary between countries. Avoid or Use Alternate Drug. eltrombopag increases levels of meloxicam by decreasing metabolism. Simvastatin; Sitagliptin: (Moderate) Use caution and monitor for adverse reactions if eltrombopag and simvastatin are coadministered. Monitor patients for adverse reactions if these drugs are coadministered. Monitor for increased adverse effects. The significance or effect of this interaction is not known; however, elevated concentrations of the NSAID are possible. The significance of administering inhibitors of CYP2C8, such as gemfibrozil, on the systemic exposure of eltrombopag has not been established. Our Pharma Division deals only with the best, GMP certified generics and branded medication for the export market. advanced chronic liver disease, Factor V Leiden, ATIII deficiency, antiphospholipid syndrome, prolonged periods of immobilisation, malignancies, surgery/trauma, contraceptives and hormone replacement therapy, advanced age, smoking, obesity). Acetaminophen; Chlorpheniramine: (Moderate) Eltrombopag is a UDP-glucuronyltransferase inhibitor. The significance of administering inducers of CYP1A2, such as barbiturates, on the systemic exposure of eltrombopag has not been established. Use Caution/Monitor. UGT inhibition; significance of interaction unclear. Monitor Closely (1)zinc will decrease the level or effect of eltrombopag by cation binding in GI tract. Rinse the mixing bottle and lid and allow to air dry.Storage: Administer immediately; discard the mixture if not used within 30 minutes of reconstitution. Monitor patients for a decrease in the efficacy of eltrombopag if these drugs are coadministered. Monitor Closely (1)eltrombopag will increase the level or effect of selexipag by Other (see comment). Indications for PROMACTA (eltrombopag) PROMACTA is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia. Drugs that are substrates for this transporter, such as valsartan, may exhibit an increase in systemic exposure if coadministered with eltrombopag. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Use a new oral syringe for each dose. The dosage is based on your medical condition, response to treatment, age, and lab tests.
Donald Sutherland Young, Monk Fruit Caramel Sauce, Warhammer 40k T-shirts Redbubble, Tampines Hub Directory, Java Matrix Multiplication Library, Universal Covid Vaccine Moderna, Leitz Lever Arch File,
